GPR110 overexpression in prostate benign hyperplasia and cancer. (A) GPR110 expression, in prostate cancer lines PC-3, LNCaP, and DU145, as measured by qPCR with an exon junction 2-3 Taqman probe; and GUSB, glucuronidase beta, as a standard. (B) Immunohistochemistry on two benign prostate hyperplasia cores, BPH-1 (upper) and BPH-2 (lower). Left, stained with antibody LS-A2021; right, consecutive sections of the same cores, stained with antibody to PSA. No staining was observed with secondary and irrelevant primary antibody (not shown). Note that the LS-A2021 positive cells are PSA negative, and vice versa (arrows). (C) Consecutive paraffin sections of two different prostate adenocarcinoma cores (1 and 2, left and right, respectively), stained with LS-A2021 antibody (upper two pictures) or LS-A2019 antibody (lower two pictures). Note that staining by the one antibody excludes staining by the other antibody.